W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > February 2011

Re: beefing up PharmaOntology Queries #Q6

From: Matthias Samwald <samwald@gmx.at>
Date: Tue, 15 Feb 2011 07:09:41 +0100
Message-ID: <7820C0C196134BAC87D7F421A1197723@zetsu>
To: "Eric Prud'hommeaux" <eric@w3.org>, <public-semweb-lifesci@w3.org>
Cc: "Helena Deus" <helenadeus@gmail.com>
Hi Eric,

I'm not an expert, but this seems a bit hard to answer. Bapineuzumb does not 
seem to bind or directly regulate Apolipoprotein and its variants. The APOE4 
allele is merely a biomarker which can be used to stratify the patient 
population into likely responders and non-responders. Looking at the HCLS 
KB, TMKB and http://lod.openlinksw.com, the (almost) only information that 
can be found about Bapineuzumab are clinical trials from LinkedCT. 
hypothesis.alzforum.org does not have much either, unfortunately.

 - Matthias

From: "Eric Prud'hommeaux" <eric@w3.org>
Sent: Monday, February 14, 2011 10:37 PM
To: <public-semweb-lifesci@w3.org>
Cc: "Helena Deus" <helenadeus@gmail.com>
Subject: beefing up PharmaOntology Queries #Q6

> Query six¹ matches patients without the APOE4 allel, putatively to
> match the inclusion criterial for a clinical trial involving
> Bapineuzumab. Do we have any drug data which links Bapineuzumab to
> APOE4, so that we query for *any* protein regulated by Beelzebub,
> rather than specifically APOE4?
> ¹ 
> http://www.w3.org/wiki/HCLSIG/PharmaOntology/Queries#Q6._Are_there_any_AD_patients_without_the_APOE4_allele_as_these_would_be_good_candidates_for_the_clinical_trial_involving_Bapineuzumab.3F
> -- 
> -ericP
Received on Tuesday, 15 February 2011 06:10:21 UTC

This archive was generated by hypermail 2.3.1 : Wednesday, 7 January 2015 14:52:45 UTC